Duration of neuroprotective treatment for ischemic stroke

Stroke

Volumn 29, Issue 2, 1998, Pages 535-542

  Dyker, A G ^a   Lees, K R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Cerebral ischemia; Drug therapy; Glutamates; N methyl D aspartate; Neuroprotection; Penumbra

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; EXCITOTOXIN; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TIRILAZAD;

AUTOREGULATION; BLOOD CLOT LYSIS; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW;

EID: 0031886652     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.2.535     Document Type: Review

References (54)

1. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, La Rue L. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke: results of a phase 2a randomized trial. Stroke. 1995;26:602-605.
4. Peters GR, Hwang L-J, Musch B, Brosse DM, Orgogozo JM. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in patients with acute ischemic stroke (TESS Study). Stroke. 1996;27:195. Abstract.
5. De Deyn PP. The Piracetam in Acute Stroke Study (PASS). Eur J Neurol. 1995;2:7.
6. Pulsinelli W, Brierley J, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol. 1982;11:491-498.
7. Heiss WD. Flow thresholds of functional and morphological damage of brain tissue. Stroke. 1983;14:331.
8. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12:725.
9. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
10. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M, for the MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet. 1995;345:5.
11. Multicentre Acute Stroke Trial-Italy (MAST-1) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-14.
12. Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, Martinez-Vila E, Dycka J, Tettenborn D. Meta-analysis of oral nimodipine trials in acute ischaemic stroke. Cerebrovasc Dis. 1994;4: 197-203.
13. Steinberg GK, Perez-Pinzon MA, Maier CM, Sun GH, Yoon E, Kunis DM, Bell TE, Powell M, Kotake A, Giffard R. CGS-19755: correlation of in vitro neuroprotection, protection against experimental ischemia and CSF levels in cerebrovascular surgery patients. In: Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia, July 20-22, 1994. Marburg, Germany. Abstract, p 28.
14. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
15. Muir KW, Lees KR, Hamilton SJ, George CF. Tolerability and safety of 619C89 in acute stroke. Stroke. 1995;26:157. Abstract.
16. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. The effects of lifarizine in acute cerebral infarction: a pilot safety study. Cerebrovasc Dis. 1995;6:156-160.
17. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
18. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci. 1984;4:1884-1891.
19. Olney JR. Neurotoxicity of excitatory amino acids. In: McGreer EG, Olney JW, McGreer PJ, eds. Kainic Acid as a Tool in Neurobiology. New York, NY: Raven Press; 1978:95-171.
20. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neuroscience. 1985;58:293-297.
21. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol. 1992;34: 106-114.
22. Brailowsky S, Knight RT, Blood K, Scabini D. γ-Aminobutyric acid-induced potentiation of cortical hemiplegia. Brain Res. 1986;362:322-330.
23. Lyden PD, Lonzo L. Combination therapy protects ischemic brain in rats. Stroke. 1994;25:189-196.
24. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke. 1996;27:1453-1458.
25. He YY, Hsu CY, Erzin AM, Miller MS. Polyethylene glycol-conjugated superoxide dismutase in focal cerebral ischemia-reperfusion. Am J Physiol. 1993;265:1:34-41.
26. del Zoppo GJ, Schmid-Schönbein GW, Mori E, Copeland BR, Chang C-M. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke. 1991;22: 1276-1283.
27. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke. 1991;22:877-883.
28. Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR, Todd RF III. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol. 1994;35:447-452.
29. Chopp M, Zhan RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25: 869-876.
30. Jiang N, Moyle M, Soule HR, Rote W, Chopp M. Neutrophil inhibitory factor is neuroprotective after focal ischaemia in rats. Ann Neurol. 1995;38: 935-942.
31. Grosset DG, Muir KW, Lees KR. Systemic and cerebral haemodynamic responses to the non-competitive N-methyl-D-aspartate (NMDA) antagonist CNS1102. J Cardiovasc Pharmacol. 1995;25:705-709.
32. Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS1102 in normal volunteers. Br J Clin Pharmacol. 1994;38:33-38.
33. Muir KW, Lees KR. Initial experience with remacemide hydrochloride in patients with acute ischemic stroke. Ann N Y Acad Sci. 1995;765:322-323.
34. Reggiani A, Costa S, Pietra C, Ratti E, Trist D, Ziviani L, Gaviraghi G. Neuroprotective activity of GV150526, a novel potent and selective glycine antagonist. Eur J Neurol. 1995;(suppl 2):6.
35. Wester PO, Asplund K, Eriksson S, Hagg E, Lithner F, Strand T. Infusion of magnesium in patients with acute brain infarction. Acta Neurol Scand. 1984;70:143. Abstract.
36. Muir KW, Lees KR. A randomized, double-blind, placebo controlled trial of intravenous magnesium sulphate in acute stroke. Stroke. 1995;26: 1183-1188.
37. Muir KW, Lees KR. Dose ranging study of magnesium sulphate after acute stroke. Eur J Neurol. 1995;2(suppl 2):7-8.
38. Collins R, Peto R, Flather M, Parish S, Sleight P, Conway M, Pipilis A, Baigent C, Barnett D, Boissel JP, Budaj A, Cairns J, Ceremuzynski L, Cohen AF, De Backer G, Diaz R, Dienstl F, Dove P. ISIS 4: a randomised factorial trial assessing oral captopril, oral mononitrate, and iv magnesium sulphate in 58,050 patients with suspected myocardial infarction. Lancet. 1995;345:669-685.
39. Wahlgren NG, MacMahon DG, De Keyser J, Indredavic B, Ryman T, for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1994;2:204-210.
40. Kurumaji A, Ikeda M, Dewar D, McCormack AG, McCulloch J. Effects of chronic administration of MK-801 upon local cerebral glucose utilisation and ligand binding to the NMDA receptor complex. Brain Res. 1991;563: 57-65.
41. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, Farber N, Wozniak DF, Olney JW. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyly-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplemal cortex. Exp Neurol. 1993;123:204-215.
42. Symon L, Pasztor E, Branston NM. The distribution and density of reduced cerebral blood flow following acute middle cerebral artery occlusion: an experimental study by the technique of hydrogen clearance in baboons. Stroke. 1974;5:355-364.
43. Kaplan B, Brint S, Tanabe J, Jacewicz M, Wang X, Pulsmelli W. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. Stroke. 1991;22:1032-1039.
44. Ackerman RH, Lev MH, Mackay BC, Katz PM, Babikian VL, Alpert NM, Correia JA, Panagos PD, Senda M. PET studies in acute stroke: findings and relevance to therapy. J Cereb Flow Metab. 1989;(suppl 1):S359.
45. Baron JC, Bousser MG. Comar D, Rougemont D, Lebrun-Grandié P, Castaigne P. Apport de la tomographie par emission de positrons dans l'etude phyhsiopathologique de l'ischemic cerebrale chex l'homme. Presse Med. 1983;12:3066-3072.
46. Baron JC, Bousser MG, Comar D, Soussaline F, Castaigne P. Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo: potentials, limitations, and clinical applications in cerebral ischemic disorders. Eur Neurol. 1981;20:273-284.
47. Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab. 1992;12:193-203.
48. Bullock R, Zauner A, Woodward J, Young HF. Massive persistent release of excitatory ammo acids following human occlusive stroke. Stroke. 1995; 20:2187-2189.
49. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke. 1990;21:848-853.
50. Moore WS, Barnett HJ, Beebe HG, Bernstein EF, Brener BJ, Brott T, Caplan LR, Day A, Goldstone J, Hobson RW II, et al. Guidelines for carotid endarterectomy: a multidisciplinary consensus statement from the Ad Hoc Committee of the American Heart Association. Stroke. 1995;26: 188-201.
51. Yasaka M, Yamaguchi T, Oita J, Sawada T, Shichiri M, Omae T. Clinical features of recurrent embolization in acute cardioembolic stroke. Stroke. 1993;24:1681-1685.
52. Weir CJ, Murray GD, Adams FG, Muir KW, Grosset DG, Lees KR. Poor accuracy of stroke scoring systems for differential clinical diagnosis of intracranial haemorrhage and infarction. Lancet. 1994;344:999-1002.
53. Bullock R, Graham DI, Swanson S, McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischaemia in the cat. J Cereb Blood Flow Metab. 1994;14:466-471.
54. Fieschi C, Lenzi GL. Cerebral blood flow and metabolism in stroke patients. In: Russell RW, ed. Vascular Diseases of the Central Nervous System. New York, NY: Churchill Livingstone Inc: 1983:101-127.